VC
Value Add VC
⚡HomePulse⚡Helpful Apps📝Blog🤝Partner
Illustration for: What BofA's Extreme Bull Signal Means for Your Marks
Value Add VC/Pulse/IPOTRACE'S TAKE

What BofA's Extreme Bull Signal Means for Your Marks

BofA's Bull & Bear indicator hit 9.7, its highest since 2021 and above the firm's own 8.0 sell threshold — a trace's-take on what that extreme reading should change about how GPs mark portfolio companies against public comps.

By the Numbers

9.7
BofA reading
8.0
Sell threshold
$195-205B
Alphabet capex guide
$18.4B
SpaceX Q2 capex
TC
Trace Cohen
Early-stage VC & angel · Founder, New York Venture Partners
August 9, 2026
2 min read
ShareXLinkedInEmail
TC

The VC Read · Trace's Take

Trace Cohen

This is a portfolio-marking prompt, not a sell signal — run your Q3 valuations against a 15-20% comp compression before you finalize them, regardless of which way the market actually moves. Watch the next round of mega-cap earnings as the real test of whether today's multiples have room to hold.

Analysis

I don't think BofA's Bull & Bear Indicator hitting 9.7 this week — its highest reading since 2021, and comfortably above the firm's own 8.0 sell-signal threshold — is the kind of thing you sell into. Pulse covered the reading itself Friday: equity fund flows, tight credit spreads and broad market breadth all pushed the gauge past where BofA's own playbook says get defensive. But I think the more useful question for anyone marking a venture portfolio isn't whether to trim public exposure — it's what an indicator this extreme should change about how you underwrite the multiples you're using to mark private companies against their public comps.

Here's my read: an indicator sitting at 9.7 doesn't mean a correction is imminent — BofA's own history shows readings above 8.0 have sat there for weeks before anything happens, and sometimes nothing happens at all. What it does mean is that the market has very little room left to absorb a disappointing print without a sharp multiple reaction. That matters directly for GPs marking portfolio companies against public SaaS, AI-infrastructure or fintech comps right now, because those comps are trading at multiples set during exactly this kind of extreme-sentiment window — Cloudflare's stock is up 44% year to date, SpaceX has swung double digits in single sessions twice in one week, and the AI-infrastructure names carrying this market are the same ones with the least room to disappoint.

“What it does mean is that the market has very little room left to absorb a disappointing print without a sharp multiple reaction.”

If you're finalizing a 409A or a markup this quarter, I'd run the sensitivity the other direction: what does this company's implied multiple look like if its public comp set compresses 15-20%, not what it looks like today. That's not a prediction the correction happens on any particular timeline — it's just matching your risk assumption to what the sentiment data is actually telling you, which is that today's multiples have very little margin for error built in.

Room for disagreement: BofA's indicator has thrown false-alarm sell signals before, and reading a hard correction into one number ignores that the S&P and Nasdaq both rallied the same week the gauge hit its high — real earnings strength, with Cloudflare's beat-and-raise and Alphabet and Microsoft both guiding capex higher rather than lower according to the Motley Fool, is arguably a better predictor of near-term direction than a positioning gauge that's mechanically driven by fund flows and credit spreads rather than fundamentals. A GP who marks down every portfolio company every time a sentiment indicator gets stretched will systematically under-mark good companies during exactly the periods when they're compounding fastest.

Either way, the number I'm actually watching next isn't the indicator itself — it's whether the next round of mega-cap earnings gives the market a reason to test that 8.0 threshold for real, or gives it one more quarter of cover to stay stretched.

ShareXLinkedInEmail

Reported by Value Add Pulse Analysis · Analysis by Value Add Pulse.

← Back to Pulse

THE WIRE in your inbox— Tech, startup & VC news with Trace's take. Free, no spam.

Read Next

IPO· Aug 8, 2026

Biotech IPOs Are Pricing Above Range Again

Illustration for: Biotech IPOs Are Pricing Above Range Again
IPO$532.5M combined

Biotech IPOs Are Pricing Above Range Again

BlossomHill and Braveheart Bio both upsized and priced above their original ranges this week, the clearest two-deal signal yet that the biotech IPO window -- closed to all but the strongest names in 2024-2025 -- is reopening.

IPO· Aug 7, 2026

BlossomHill Prices Upsized $150M IPO, Debuts on Nasdaq

Illustration for: BlossomHill Prices Upsized $150M IPO, Debuts on Nasdaq
IPO$150M IPO

BlossomHill Prices Upsized $150M IPO, Debuts on Nasdaq

BlossomHill Therapeutics priced an upsized IPO at $16 a share for $150M and began trading on Nasdaq under BLSM, more than 50% above the $100M target Pulse flagged when the company first filed.

IPO· Aug 7, 2026

BofA's Sell Signal Hits Highest Level Since 2021

Illustration for: BofA's Sell Signal Hits Highest Level Since 2021
IPO

BofA's Sell Signal Hits Highest Level Since 2021

Bank of America's Bull & Bear sentiment indicator jumped to 9.7 -- its highest reading since 2021 and above the firm's own 8.0 sell-signal threshold -- even as the S&P 500 and Nasdaq both rallied Friday on weak jobs data.

@Trace_Cohen·t@nyvp.com